CHEK vs. CLGN, NXGL, IRIX, PETV, NXL, XAIR, NRXS, LFWD, VVOS, and ICU
Should you be buying Check-Cap stock or one of its competitors? The main competitors of Check-Cap include CollPlant Biotechnologies (CLGN), NEXGEL (NXGL), IRIDEX (IRIX), PetVivo (PETV), Nexalin Technology (NXL), Beyond Air (XAIR), NeurAxis (NRXS), ReWalk Robotics (LFWD), Vivos Therapeutics (VVOS), and SeaStar Medical (ICU). These companies are all part of the "medical equipment" industry.
Check-Cap vs.
CollPlant Biotechnologies (NASDAQ:CLGN) and Check-Cap (NASDAQ:CHEK) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, community ranking, media sentiment, dividends and profitability.
CollPlant Biotechnologies has higher revenue and earnings than Check-Cap. CollPlant Biotechnologies is trading at a lower price-to-earnings ratio than Check-Cap, indicating that it is currently the more affordable of the two stocks.
Check-Cap has a net margin of 0.00% compared to CollPlant Biotechnologies' net margin of -2,680.00%. Check-Cap's return on equity of 0.00% beat CollPlant Biotechnologies' return on equity.
21.7% of CollPlant Biotechnologies shares are owned by institutional investors. Comparatively, 1.1% of Check-Cap shares are owned by institutional investors. 9.6% of CollPlant Biotechnologies shares are owned by company insiders. Comparatively, 0.5% of Check-Cap shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
CollPlant Biotechnologies has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500. Comparatively, Check-Cap has a beta of 0.21, indicating that its stock price is 79% less volatile than the S&P 500.
In the previous week, Check-Cap had 1 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 1 mentions for Check-Cap and 0 mentions for CollPlant Biotechnologies. CollPlant Biotechnologies' average media sentiment score of 0.00 equaled Check-Cap'saverage media sentiment score.
Check-Cap received 229 more outperform votes than CollPlant Biotechnologies when rated by MarketBeat users. Likewise, 60.76% of users gave Check-Cap an outperform vote while only 60.00% of users gave CollPlant Biotechnologies an outperform vote.
CollPlant Biotechnologies presently has a consensus price target of $12.50, indicating a potential upside of 531.31%. Given CollPlant Biotechnologies' stronger consensus rating and higher probable upside, equities research analysts clearly believe CollPlant Biotechnologies is more favorable than Check-Cap.
Summary
CollPlant Biotechnologies beats Check-Cap on 10 of the 17 factors compared between the two stocks.
Get Check-Cap News Delivered to You Automatically
Sign up to receive the latest news and ratings for CHEK and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Check-Cap Competitors List
Related Companies and Tools
This page (NASDAQ:CHEK) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy CHEK Stock Free CHEK Stock Alerts